Study of the impact of CYP2C19 gene polymorphism and H.pylori eradication in the treatment of ulcers PPI after endoscopic treatment(ESD:endoscopic submucosal dissection) of gastric neoplasm

Study of the impact of CYP2C19 gene polymorphism and H.pylori eradication in the treatment of ulcers PPI after endoscopic treatment(ESD:endoscopic submucosal dissection) of gastric neoplasm - Study of the impact of CYP2C19 gene polymorphism and H.pylori eradication in PPI treatment of after ESD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015790

Enrollment

200

Registered

2014-11-29

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer, gastric adenoma

Interventions

eradication of H. pylori before ESD treatment eradication of H. pylori after ESD treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as early gastric cancer or gastric adenoma and are considered as the indication of ESD treatment

Exclusion criteria

Exclusion criteria: 1.H.pylor-negative patients 2.Patiants with surgical history of stomach 3.patients who are pregnant or nursing 4.patients who are diagnosed as unsuitable for this trial by investigatior

Design outcomes

Primary

Measure	Time frame
the healing rates of artificial ulcer at 4 and 8 weeks late of ESD treatment	—

Secondary

Measure	Time frame
ESD-related complications such as bleeding or perforation	—

Countries

Japan

Contacts

Public ContactYashiro Yoshizawa

Seirei Hamamatsu General Hospital Department of Gastroenterology

yashiro1224@sis.seirei.or.jp053-474-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026